Journal
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
Volume 13, Issue 4, Pages 471-483Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10911-008-9104-6
Keywords
Receptor; IGF Type I; IGF-1R inhibition; Monoclonal antibody; Tyrosine kinase inhibitors; Clinical trials-Phase I; Clinical trials-Phase II; Drug resistance; Receptor crosstalk
Categories
Funding
- Mayo Clinic Breast [CA116201-01]
- NIH K12 [CA090628-05]
- Fred C. and Katherine B. Andersen Foundation
- Mayo Clinic Cancer Center [CA15083]
- NATIONAL CANCER INSTITUTE [P30CA015083, P50CA116201, K12CA090628] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The insulin-like growth factor pathway plays a major role in cancer cell proliferation, survival and resistance to anti-cancer therapies in many human malignancies, including breast cancer. As a key signaling component of IGF system, the IGF-1 receptor is the target of several investigational agents in clinical and pre-clinical development. This review will focus on the rationale for targeting the IGF-1 receptor and other components of the IGF-1 system. In addition, we will examine the role of IGF-1 signaling in resistance to clinically important breast cancer therapies, including cytotoxic chemotherapy, hormonal therapy and erbB targeted agents. We will also review the completed and ongoing clinical investigations with IGF-1 receptors inhibitors to date and the utility of these early data in designing future breast cancer studies with IGF-1 signaling inhibition strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available